Manages pain severe enough to require an opioid analgesic. ANDA 70918, held by Hospira. Nalbuphine Hydrochloride.
As of Nov 22, 2026, ANDA 70918 (Nalbuphine Hydrochloride), held by Hospira, was first approved by FDA on Feb 3, 1989, with 18 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Nalbuphine Hydrochloride Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Nalbuphine Hydrochloride Injection can also be used as a supplement to balanced anesthesia, for preoperative and postoperative analgesia, and for obstetrical analgesia during labor and delivery. Limitations of Use: Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, reserve Nalbuphine Hydrochloride Injection for use in patients for whom alternative treatment options (e.g.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 3, 1989 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Nalbuphine Hydrochloride200MG/10ML (20MG/ML) · solution;intramuscular, intravenous, subcutaneous | Nalbuphine Hydrochloride | Rx |
| Dec 22, 2025 | Supplement 38Labeling · Standard review | Approved | None posted |
| Aug 27, 2024 | Supplement 36Labeling · Standard review | Approved | None posted |
| Dec 15, 2023 | Supplement 34Labeling · Standard review | Approved | None posted |
| Dec 1, 2023 | Supplement 29Labeling · Standard review | Approved | None posted |
| Oct 16, 2019 | Supplement 28Labeling · Standard review | Approved | None posted |
| Dec 16, 2016 | Supplement 25Labeling · Standard review | Approved | None posted |
| Dec 16, 2016 | Supplement 26Labeling · Standard review | Approved | None posted |
| Nov 30, 2007 | Supplement 18Labeling | Approved | None posted |
| Oct 25, 2002 | Supplement 14Manufacturing | Approved | None posted |
| Jul 12, 1999 | Supplement 13Manufacturing | Approved | None posted |
| May 5, 1998 | Supplement 12Manufacturing | Approved | None posted |
| Feb 27, 1997 | Supplement 9Manufacturing | Approved | None posted |
| Feb 27, 1997 | Supplement 10Manufacturing | Approved | None posted |
| Feb 27, 1997 | Supplement 11Manufacturing | Approved | None posted |
| Oct 3, 1996 | Supplement 8Manufacturing | Approved | None posted |
| Apr 26, 1996 | Supplement 5Labeling | Approved | None posted |
| Feb 28, 1991 | Supplement 3Labeling | Approved | None posted |
| Jul 25, 1990 | Supplement 2Labeling | Approved | None posted |
| Feb 3, 1989 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters